- Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
- Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
- Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
- Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
More ▼
Key statistics
On Tuesday, Aligos Therapeutics Inc (ALGS:NAQ) closed at 0.55, 57.96% above the 52 week low of 0.3482 set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.56 |
---|---|
High | 0.561 |
Low | 0.5298 |
Bid | 0.530 |
Offer | 0.56 |
Previous close | 0.5595 |
Average volume | 424.58k |
---|---|
Shares outstanding | 78.11m |
Free float | 59.58m |
P/E (TTM) | -- |
Market cap | 43.70m USD |
EPS (TTM) | -1.51 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:00 BST.
More ▼